Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Saskia Hussung"'
Autor:
Marco Cefalì, Isabel Scala, Giuliana Pavone, Daniel Helbling, Saskia Hussung, Ralph Fritsch, Cäcilia Reiner, Soleen Stocker, Dieter Koeberle, Marc Kissling, Vito Chianca, Filippo Del Grande, Sara De Dosso, Stefania Rizzo
Publikováno v:
Cancers, Vol 15, Iss 17, p 4398 (2023)
Background: Malnutrition, loss of weight and of skeletal muscle mass are frequent in pancreatic cancer patients, a majority of which will undergo chemotherapy over the course of their disease. Available data suggest a negative prognostic role of thes
Externí odkaz:
https://doaj.org/article/93b30554ff8544238104a15a6f43bb9c
Autor:
Marie-Claire Rittmann, Saskia Hussung, Lukas M. Braun, Rhena F. U. Klar, Esther A. Biesel, Stefan Fichtner-Feigl, Ralph Fritsch, Uwe A. Wittel, Dietrich A. Ruess
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a disease with a very unfavorable prognosis. Surgical resection represents the only potentially curative treatment option, but recurrence after complete resection is almost certain. In an explorator
Externí odkaz:
https://doaj.org/article/eed841e9d8bb480f8aa6de85bb380eea
Autor:
Saskia Hussung, Dilara Akhoundova, Julian Hipp, Marie Follo, Rhena F. U. Klar, Ulrike Philipp, Florian Scherer, Nikolas von Bubnoff, Justus Duyster, Melanie Boerries, Uwe Wittel, Ralph M. Fritsch
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Novel biomarkers and molecular monitoring tools hold potential to improve outcome for patients following resection of pancreatic ductal adenocarcinoma (PDAC). We hypothesized that the combined longitudinal analysis of mutated cell
Externí odkaz:
https://doaj.org/article/df151022f76648449f2bf707053b3b13
Precision Oncology for Hepato-Pancreato-Biliary (HPB) Cancers State of the Art and Future Directions
Publikováno v:
healthbook TIMES. Oncology Hematology, Vol 5, Iss 3 (2020)
The revolution of precision medicine is rapidly changing the way we diagnose and treat cancer. The wide availability of comprehensive molecular profiling has led to the rapid accumulation of a wealth of molecular data, and no medical oncologist can e
Externí odkaz:
https://doaj.org/article/42bebf32cce44bbf957b83b5a26682af
Autor:
Birte Kulemann, Stephanie Rösch, Sindy Seifert, Sylvia Timme, Peter Bronsert, Gabriel Seifert, Verena Martini, Jasmina Kuvendjiska, Torben Glatz, Saskia Hussung, Ralph Fritsch, Heiko Becker, Martha B. Pitman, Jens Hoeppner
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease. Circulating tumor cells (CTC) in the blood are hypothesized as the means of systemic tumor spread. Blood obtained from healthy donors and patients with PDAC was therefore subj
Externí odkaz:
https://doaj.org/article/3c8818e189834f428dc9c5e17abf9a17
Autor:
Julius Wehrle, Ulrike Philipp, Martina Jolic, Marie Follo, Saskia Hussung, Silvia Waldeck, Max Deuter, Michael Rassner, Jan Braune, Justyna Rawluk, Christine Greil, Cornelius F. Waller, Heiko Becker, Jesús Duque-Afonso, Anna L. Illert, Ralph M. Fritsch, Frank Meiss, Justus Duyster, Nikolas von Bubnoff, Florian Scherer
Publikováno v:
Diagnostics, Vol 10, Iss 8, p 550 (2020)
Background: Circulating tumor DNA (ctDNA) in the blood plasma of cancer patients is an emerging biomarker used across oncology, facilitating noninvasive disease monitoring and genetic profiling at various disease milestones. Digital droplet PCR (ddPC
Externí odkaz:
https://doaj.org/article/e63030888c5d4ece9ce2c4dc54ca2dd8
Autor:
Lukas M. Braun, Simon Lagies, Rhena F. U. Klar, Saskia Hussung, Ralph M. Fritsch, Bernd Kammerer, Uwe A. Wittel
Publikováno v:
Cancers, Vol 12, Iss 6, p 1440 (2020)
Pancreatic ductal adenocarcinoma (PDAC) is associated with high mortality and will become the second most common cause of cancer-associated mortality by 2030. The poor prognosis arises from a lack of sensitive biomarkers, limited therapeutic options,
Externí odkaz:
https://doaj.org/article/f5a87ba1523d456685bc78484bc7d65d
Autor:
Hagen Klett, Hannah Fuellgraf, Ella Levit-Zerdoun, Saskia Hussung, Silke Kowar, Simon Küsters, Peter Bronsert, Martin Werner, Uwe Wittel, Ralph Fritsch, Hauke Busch, Melanie Boerries
Publikováno v:
Frontiers in Genetics, Vol 9 (2018)
Late diagnosis and systemic dissemination essentially contribute to the invariably poor prognosis of pancreatic ductal adenocarcinoma (PDAC). Therefore, the development of diagnostic biomarkers for PDAC are urgently needed to improve patient stratifi
Externí odkaz:
https://doaj.org/article/7676b7b973824581a3fe81105ce3ebeb
Autor:
Dilara Akhoundova, Saskia Hussung, Smruthy Sivakumar, Antonia Töpfer, Markus Rechsteiner, Abdullah Kahraman, Fabian Arnold, Florian Angst, Christian Britschgi, Martin Zoche, Holger Moch, Achim Weber, Ethan Sokol, Ralph M. Fritsch
Publikováno v:
Akhoundova, Dilara; Hussung, Saskia; Sivakumar, Smruthy; Töpfer, Antonia; Rechsteiner, Markus; Kahraman, Abdullah; Arnold, Fabian; Angst, Florian; Britschgi, Christian; Zoche, Martin; Moch, Holger; Weber, Achim; Sokol, Ethan; Fritsch, Ralph M (2022). ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer. International journal of cancer, 151(12), pp. 2161-2171. Wiley-Blackwell 10.1002/ijc.34257
c-Ros oncogene 1, receptor tyrosine kinase (ROS1) genomic rearrangements have been reported previously in rare cases of colorectal cancer (CRC), yet little is known about the frequency, molecular characteristics, and therapeutic vulnerabilities of RO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7de68fab5acf34d23136a348c94a31c
https://boris.unibe.ch/174912/1/Intl_Journal_of_Cancer_-_2022_-_Akhoundova_-_ROS1_genomic_rearrangements_are_rare_actionable_drivers_in_microsatellite.pdf
https://boris.unibe.ch/174912/1/Intl_Journal_of_Cancer_-_2022_-_Akhoundova_-_ROS1_genomic_rearrangements_are_rare_actionable_drivers_in_microsatellite.pdf
Autor:
Ralph Fritsch, Pierre-Alain Clavien, Mickael Lesurtel, Francesco Minni, Michelle L. DeOliveira, Saskia Hussung, Thomas J. Meyer, Christian E. Oberkofler, Thomas Brunner, Bernhard C. Pestalozzi, Riccardo Casadei, Susanne Merkel, Christiane Bruns, Carlo Ingaldi, Sarah R. Haile, Carla Serra, Claudio Ricci, Stefan Heinrich, Wolf O. Bechstein, Robert Grützmann, Alessandra Guido, Henriette Golcher, Henrik Petrowsky, Mariacristina Di Marco, Milo A. Puhan, Dominique Lisa Birrer, Rainer Fietkau
Publikováno v:
Annals of Surgery. 274:713-720
Objective The aim of this study was to pool data from randomized controlled trials (RCT) limited to resectable pancreatic ductal adenocarcinoma (PDAC) to determine whether a neoadjuvant therapy impacts on disease-free survival (DFS) and surgical outc